ClinicalTrials.gg
Not yet recruitingNCT07795268Updated Aug 31, 2026

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 3 interventional study of 177Lu-NYM032 injection and Best supportive/best standard of care in Prostate Cancer, sponsored by Norroy Bioscience Co., LTD. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Norroy Bioscience Co., LTD · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.

Read the detailed description

Patients with PSMA positive scans will be randomized in a 2:1 ratio to receive either 177Lu-NYM032 plus best supportive/best standard of care or to receive best supportive/best standard of care only. Best supportive/best standard of care will be determined by the treating physician/investigator but will exclude investigational agents, cytotoxic chemotherapy, other systemic radioisotopes, and hemi-body radiotherapy. Novel androgen receptor pathway inhibitor (ARPI) (such as abiraterone or enzalutamide) are allowed.

This open-label study consists of a 12-month enrollment phase and a 24-month follow-up phase. During the whole study period, assessments will include monitoring of patient survival, disease progression, and adverse events.

A long-term follow-up period will include the collection of rPFS survival and information about new treatments, responses to new treatments, adverse events assessment, as well as blood for hematology and chemistry testing. During follow-up, patients will be contacted every 3 months (+/- 14 Days) via phone, email, or letter for 24 months or until 384 deaths have occurred.

An End-of-Treatment (EOT) visit should occur once a participant discontinues study treatment for any reason. This visit should occur within 7 days of the last dose of study treatment or the date the investigator becomes aware of treatment discontinuation (whichever occurs later), but before the initiation of any subsequent anticancer therapy.

A Safety Follow-up visit should occur 28 days (+7 days) after the participant's last dose of 177Lu-NYM032 Injection or the date the investigator becomes aware of treatment discontinuation (whichever occurs later), but before the initiation of any subsequent anticancer therapy outside of what is permitted by the study.

02

Conditions studied

  • Prostate Cancer

Browse trials for

03

In context

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's planned enrollment of 600 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Norroy Bioscience Co., LTD is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be male and aged ≥18 years old.
  2. Patients must have histological, pathological, and/or cytological confirmation of prostate cancer.
  3. Patient's serum/plasma testosterone level must be at a castrate level (\<50 ng/dL or \<1.7 nmol/L).
  4. Participants must have ≥1 lesion that is present on baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization.
  5. Patients must have progressive mCRPC. Documented progressive mCRPC will be based on at least 1 of the following criteria:

    • Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
    • Soft-tissue progression defined [PCWG3-modified v1.1 (Eisenhauer et al 2009, Scher et al 2016)]
    • Progression of bone disease: appearance of 2 or more new bone lesions on bone scan (PCWG3 criteria (Scher et al 2016))
  6. Patients must have a positive 68Ga-NYM032 PET/CT scan.
  7. Patients must have an performance status of 0 to 2.
  8. Patients must have a ≥ 6 months.
  9. Participants must have been previously treated with at least 1 novel androgen receptor pathway inhibitor (ARPI) (e.g., abiraterone and/or enzalutamide) and at least 1, but no more than 2, previous taxane-based chemotherapy regimens. A taxane-based chemotherapy regimen is defined as a minimum exposure of 2 cycles of a taxane. If a participant has received only 1 taxane-based chemotherapy regimen, the participant is eligible : if the participant is unwilling to receive a second taxane-based chemotherapy regimen or if the participant's physician deems the participant unsuitable to receive a second taxane-based chemotherapy regimen (e.g., frailty assessed by geriatric or health status evaluation, intolerance, etc.).
  10. Patients must have adequate organ function:

    1. Bone marrow reserve:

      • White blood cell (WBC) count ≥2.5 x 109/L
      • ≥ 10.0 g/dL (9 g/dL is equivalent to 90 g/L and 5.59 mmol/L)
      • (ANC) ≥1.5 x 10\^9/L (1.5 x 10\^9/L is equivalent to 1.5 x 10\^3/µL and 1.5 x K/µL and 1.5 x 10\^3/cumm and 1500/µL)
      • ≥ 100 x 10\^9/L (100 x 10\^9/L is equivalent to 100 x 10\^3/µL and 100 x K/µL and 100 x 10\^3/cumm and 100,000/µL)
    2. Hepatic:

      • Total ≤1.5 x the institutional (ULN). For patients with known Gilbert's Syndrome ≤ 3 x ULN is permitted
      • (ALT) or aspartate aminotransferase (AST) ≤3.0 x ULN OR ≤5.0 x ULN for patients with liver metastases
    3. Renal:

      • Serum creatinine ≤1.5 x ULN and ≥50 mL/min
      • Albumin >3.0 g/dL (3.0 g/dL is equivalent to 30 g/L)
  11. For patients who have partners of :Partner and/or patient must use a method of with adequate barrier protection, deemed acceptable by the principle investigator during the study and for 6 months after last study drug administration. Patients must not donate sperm during this period.
  12. Patients must have the ability to understand and sign an approved ICF.

Exclusion criteria

Exclusion Criteria:

  1. Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies], excluding ARPI therapy;) anticancer device therapy, radiation therapy, or an drug in a clinical study within 4 weeks prior to day of randomization.
  2. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation.
  3. Previous PSMA-targeted radioligand therapy is not allowed.
  4. Patients with a history of Central Nervous System (CNS) must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving for the purposes of maintaining neurologic integrity. Patients with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired.
  5. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
  6. Any disease involving the cardiac, respiratory, renal, hepatic, or hematologic organ systems that would significantly interfere with completion of the study or confound the determination of the causality of any adverse events in the study.
  7. Severe urinary incontinence, hydronephrosis, severe voiding dysfunction, or other related conditions. Note: Participants with bladder outlet obstruction or urinary incontinence that can be managed with available best standard of care (including urinary pads, drainage, etc.) are eligible for study participation.
  8. Any toxicity related to prior anti-cancer therapies that has not recovered to ≤ Grade 2 according to v6.0, except for alopecia.
  9. Uncontrolled or cardiovascular disease, including but not limited to:

    • History of symptomatic congestive heart failure ( [NYHA] Class III to IV) or any arterial thromboembolic events (e.g., myocardial infarction, unstable angina, cerebrovascular accident, or ) within 6 months prior to randomization;
    • Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg despite antihypertensive therapy;
    • Serious cardiac arrhythmias requiring treatment;
    • Prolonged interval using Fridericia' s formula (QTcF) >450 ms (male).
  10. Clinically significant concomitant pulmonary diseases, including but not limited to:

    • History of interstitial lung disease (ILD)/interstitial pneumonia requiring steroid treatment (non-infectious), current ILD/interstitial pneumonia, or suspected ILD/interstitial pneumonia that cannot be ruled out by imaging assessment;
    • Pulmonary embolism within 3 months prior to randomization;
    • Any documented , connective tissue, or inflammatory disease at screening (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis) with suspected pulmonary involvement;
    • Prior pneumonectomy;
    • Other moderate to severe pulmonary diseases that significantly impair respiratory function and may interfere with the detection or management of drug-related pulmonary toxicity.
  11. Severe infection (NCI CTCAE ≥ Grade 3), such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications, within 4 weeks prior to randomization, or active infection requiring systemic anti-infective therapy within 2 weeks prior to randomization. Participants receiving prophylactic anti-infective therapy (e.g., prophylaxis for urinary tract infection or exacerbation) may be eligible for enrollment after discussion with the Sponsor.
  12. A superscan as seen in the baseline bone scan.
  13. Active bleeding, a history of bleeding disorders, or treatment with coumarin anticoagulants.
  14. Uncontrolled third-space fluid accumulation (e.g., pleural effusion, ascites, or pericardial effusion) requiring repeated drainage.
  15. Participants of who are unwilling to use an acceptable method of during the study and for 6 months after the last study drug administration.
  16. Diagnosed with other that are expected to alter or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are patients with adequately treated non-melanoma skin cancer, superficial bladder cancer.
  17. Active chronic infection [e.g., positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with HBV DNA ≥2,000 IU/mL or ≥5,000 copies/mL], active infection [e.g., positive hepatitis C virus (HCV) antibody with detectable HCV RNA], antibody positivity, or active syphilis infection (positive syphilis-specific antibody and non-treponemal antibody).
  18. Known to the components of the study therapy or its analogs.
  19. Transfusion for the sole purpose of making a subject eligible for study inclusion.
  20. Any disease, psychiatric condition, or surgical condition that may affect completion of the study (including poor compliance) or render the participant unsuitable for treatment with the investigational medicinal product.
  21. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    177Lu-NYM032 plus BSC/BSoC

    Patients randomized to receive the investigational product will receive 7.4 GBq (+/- 10%) 177Lu-NYM032 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BSC/BSoC) may be used.

    Drug: 177Lu-NYM032 injection · Other: Best supportive/best standard of care

  • Other
    BSC/BSoC alone

    Patients randomized to this arm will receive best supportive/best standard of care (BSC/BSoC) as determined by the investigator.

    Other: Best supportive/best standard of care

Interventions

  • Drug177Lu-NYM032 injection

    Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

  • OtherBest supportive/best standard of care

    Best supportive/best standard of care as defined by the local investigator

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as time to death due to any cause

    Time frame: From date of randomization until date of death from any cause, assessed up to 36months (estimated final OS analysis)

Secondary outcomes

  1. Radiographic progression-free survival (rPFS)

    rPFS is defined as the time to radiographic progression by PCWG3-modified RECIST v1.1 or death

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 36 months (estimated final OS analysis)

  2. Number of participants with Treatment Emergent Adverse Events

    The distribution of adverse events (AE) will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

  3. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) according to PCWG3 modified RECIST 1.1

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 36 months (estimated final OS analysis)

  4. Disease control rate (DCR)

    DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) in soft tissue according to PCWG3 modified RECIST 1.1

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 36 months (estimated final OS analysis)

  5. Duration of Response (DOR)

    DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 36 months (estimated final OS analysis)

  6. Time to first Symptomatic Skeletal Event (SSE)

    Time to SSE is defined as the date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 36 months (estimated final OS analysis)

  7. Progression-free survival (PFS)

    PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 36 months (estimated final OS analysis)

  8. Biochemical response

    Biochemical response is defined as the proportion of participants who have a greater or equal 50% decrease in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later

    Time frame: From date of randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

  9. Prostate-specific antigen 80 (PSA80) response

    PSA80 response is defined as the proportion of participants who have a greater or equal 80% decrease in PSA from Baseline that is confirmed by a second PSA measurement 4 weeks later

    Time frame: From date of randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

  10. Duration of PSA response

    Duration of PSA response is defined as the duration between the date of first document PSA response (i.e. \>= 50% decrease in PSA from Baseline) and the earliest date of PSA progression

    Time frame: From date of randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

  11. European Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)

    EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.

    Time frame: From date of randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

  12. Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life

    Time frame: From date of randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

  13. Brief Pain Inventory-short Form (BPI-SF)

    The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use

    Time frame: From date of randomization till 30 days safety follow-up, assessed up to 36 months (estimated final OS analysis)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2028, 26 months later.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 26 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 31, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Aug 31, 2029
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07795268
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Aug 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion